Phase III Trial of Pafolacianine Sodium Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
This phase III trial showed that pafolacianine sodium injection with intraoperative near-infrared fluorescence imaging detects additional lesions for surgical resection that would otherwise be missed by white light and palpation.
Format: Microsoft PowerPoint (.ppt)
File Size: 448 KB
Released: June 9, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.

Related Content

Prof Nicole Concin, MD, PhD, shares her thoughts on the application of new clinical data for ovarian and endometrial cancers in Europe in this clinical commentary from Clinical Care Options (CCO)

Nicole Concin, MD, PhD Released: December 7, 2021

Clinical commentary with Colleen Bohnenkamp, PharmD, BCOP, BCPS, and Dane Fritzsche, PharmD, BCOP, on application of new clinical data for ovarian and endometrial cancers in Europe, from Clinical Care Options (CCO)

person default Colleen Bohnenkamp, PharmD, BCOP, BCPS person default Dane Fritzsche, PharmD, BCOP Released: December 7, 2021

Podcast episode with expert insights on important trial data for ovarian and endometrial cancers from the ESGO 2021 annual meeting, from Clinical Care Options (CCO)

Nicole Concin, MD, PhD Released: November 23, 2021

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue